Head-to-head evidence
LY03009 vs SER-252 (PEOZ-apomorphine)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
LY03009
Developed by Luye Pharma Group
NCT04593511 · Phase 1 · status unknown
This open-label, single-dose pharmacokinetic study compared four different formulations of LY03009 against each other in healthy volunteers, but included no placebo or inactive control arm and no blinding. No results have been posted, and because every arm receives active drug in a different formulation, this design cannot demonstrate a treatment effect once results are available.
SER-252 (PEOZ-apomorphine)
Developed by Serina Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07422675 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY03009's landscape · SER-252 (PEOZ-apomorphine)'s landscape